180 Life Sciences (NASDAQ:ATNF – Get Rating) is one of 952 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it compare to its peers? We will compare 180 Life Sciences to related companies based on the strength of its risk, institutional ownership, valuation, earnings, dividends, profitability and analyst recommendations.
Earnings and Valuation
This table compares 180 Life Sciences and its peers top-line revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|180 Life Sciences||N/A||-$20.33 million||1.60|
|180 Life Sciences Competitors||$1.84 billion||$245.93 million||-3.85|
180 Life Sciences’ peers have higher revenue and earnings than 180 Life Sciences. 180 Life Sciences is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
|Net Margins||Return on Equity||Return on Assets|
|180 Life Sciences||N/A||59.53%||39.59%|
|180 Life Sciences Competitors||-3,209.16%||-160.26%||-24.32%|
This is a breakdown of current ratings and price targets for 180 Life Sciences and its peers, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|180 Life Sciences||0||1||0||0||2.00|
|180 Life Sciences Competitors||3105||13053||39250||634||2.67|
As a group, “Pharmaceutical preparations” companies have a potential upside of 100.42%. Given 180 Life Sciences’ peers stronger consensus rating and higher probable upside, analysts clearly believe 180 Life Sciences has less favorable growth aspects than its peers.
Institutional and Insider Ownership
7.2% of 180 Life Sciences shares are owned by institutional investors. Comparatively, 42.5% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 15.2% of 180 Life Sciences shares are owned by insiders. Comparatively, 15.0% of shares of all “Pharmaceutical preparations” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Volatility and Risk
180 Life Sciences has a beta of 0.4, meaning that its stock price is 60% less volatile than the S&P 500. Comparatively, 180 Life Sciences’ peers have a beta of 0.97, meaning that their average stock price is 3% less volatile than the S&P 500.
180 Life Sciences peers beat 180 Life Sciences on 8 of the 13 factors compared.
About 180 Life Sciences
1180 Life Sciences Corp., a clinical-stage biotechnology company, develops therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. Its product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which is under Phase IIb clinical trials that focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which is under preclinical trials that are man-made derivatives of CBD; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.
Receive News & Ratings for 180 Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 180 Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.